
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projecting an increase in GAAP earnings per diluted share, expecting $4.73 in 2025 and $5.17 in 2026, reflecting strong growth anticipated from the Human Nutrition and Health segment. In addition, the company's financial results for the second quarter of 2025 showed revenues of $255.5 million, which exceeded estimates and marked a 1% increase from the previous year, indicating consistent performance. Furthermore, with expectations for improving gross and net margins, along with a potential debt-free status by the end of next year, Balchem is well-positioned for future growth and possible accretive mergers and acquisitions due to its robust balance sheet.
Bears say
Balchem Corp's financial outlook appears negative due to several key factors, including a decline in the applicable P/E multiple from 39.6x to 37.9x, suggesting investor caution as share prices and revenue multiples of comparable companies have weakened. The company's animal health and nutrition segment reported third-quarter sales of $56.4 million, falling short of the $60 million estimate, while the industrial products segment also missed expectations with revenues of $1.4 million against a forecast of $1.6 million. Additionally, significant risks, such as anticipated slower growth in core business segments, inflationary pressures, and potential disruptions to the European operations, further heighten concerns about Balchem's future performance and market positioning.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares